Insmed reported $40.92M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acelrx Pharmaceuticals ACRX:US $ -342000 890K
Alimera Sciences ALIM:US $ 10.22M 1.78M
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Dynavax Technologies DVAX:US $ 74.03M 47.03M
Gilead Sciences GILD:US $ 5166M 549M
Heron Therapeutics HRTX:US $ 12.1M 2.39M
Insmed INSM:US $ 40.92M 1.92M
Novartis NVS:US $ 9059M 463M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Seattle Genetics SGEN:US $ 338.83M 4.33M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M